Response and relapses in pediatric Hodgkin's Lymphoma treated with chemotherapy alone

Aims: The aims of this study were to analyze the sociodemographic profile, disease characteristics, event-free survival (EFS), overall survival (OS), and risk factors for relapse in patients with Hodgkin's lymphoma (HL) treated with only chemotherapy as per unit protocol. Subject and Methods: C...

Full description

Saved in:
Bibliographic Details
Main Authors: Vineeta Gupta, Tej Bali Singh, Sanjeev Kumar Gupta
Format: Article
Language:English
Published: Thieme Medical and Scientific Publishers Pvt. Ltd. 2019-01-01
Series:Indian Journal of Medical and Paediatric Oncology
Subjects:
Online Access:http://www.ijmpo.org/article.asp?issn=0971-5851;year=2019;volume=40;issue=3;spage=341;epage=346;aulast=Gupta
Tags: Add Tag
No Tags, Be the first to tag this record!
_version_ 1850218740685209600
author Vineeta Gupta
Tej Bali Singh
Sanjeev Kumar Gupta
author_facet Vineeta Gupta
Tej Bali Singh
Sanjeev Kumar Gupta
author_sort Vineeta Gupta
collection DOAJ
description Aims: The aims of this study were to analyze the sociodemographic profile, disease characteristics, event-free survival (EFS), overall survival (OS), and risk factors for relapse in patients with Hodgkin's lymphoma (HL) treated with only chemotherapy as per unit protocol. Subject and Methods: Case records of children with HL diagnosed and treated at our center between January 2005 and December 2014 were retrospectively analyzed. Results: A total of 90 patients with mean age of 8.13 ± 2.65 years (median age 8 years; range 4.5–15 years) were diagnosed and treated for HL during the study period. Male-to-female ratio was 7.2:1. Almost 12.2% and 87.8% of patients had early and advanced stage disease, respectively. B symptoms were present in 87.8% of patients. Mean duration of symptoms was 9.66 ± 6.30 months (median 8 months; range 2–36 months). Mixed cellularity was the most common histologic type. Multiagent chemotherapy was mainstay of treatment. OS and EFS were 88.8% and 84.5%, respectively. OS in patients with or without bulky disease was 53.3% and 92.2%, respectively. Older age (≥10 years), presence of bulky disease, low hemoglobin (≤7.0 g/dl), and high leukocyte count (≥12000/mm3) at the time of diagnosis, and protocol used (cyclophosphamide, vincristine, procarbazine, and prednisone) were the risk factors for relapse. Conclusions: Our patient population had younger age, advanced disease, more B symptoms, and bulky disease. Still, we achieved good OS and EFS with chemotherapy-alone protocols. Patients with bulky disease had poor OS and EFS. If radiotherapy is included in the protocol for bulky disease, the survival rates can be improved further.
format Article
id doaj-art-7a3cceec57c6409785bef12408fac773
institution OA Journals
issn 0971-5851
0975-2129
language English
publishDate 2019-01-01
publisher Thieme Medical and Scientific Publishers Pvt. Ltd.
record_format Article
series Indian Journal of Medical and Paediatric Oncology
spelling doaj-art-7a3cceec57c6409785bef12408fac7732025-08-20T02:07:37ZengThieme Medical and Scientific Publishers Pvt. Ltd.Indian Journal of Medical and Paediatric Oncology0971-58510975-21292019-01-0140334134610.4103/ijmpo.ijmpo_13_18Response and relapses in pediatric Hodgkin's Lymphoma treated with chemotherapy aloneVineeta GuptaTej Bali SinghSanjeev Kumar GuptaAims: The aims of this study were to analyze the sociodemographic profile, disease characteristics, event-free survival (EFS), overall survival (OS), and risk factors for relapse in patients with Hodgkin's lymphoma (HL) treated with only chemotherapy as per unit protocol. Subject and Methods: Case records of children with HL diagnosed and treated at our center between January 2005 and December 2014 were retrospectively analyzed. Results: A total of 90 patients with mean age of 8.13 ± 2.65 years (median age 8 years; range 4.5–15 years) were diagnosed and treated for HL during the study period. Male-to-female ratio was 7.2:1. Almost 12.2% and 87.8% of patients had early and advanced stage disease, respectively. B symptoms were present in 87.8% of patients. Mean duration of symptoms was 9.66 ± 6.30 months (median 8 months; range 2–36 months). Mixed cellularity was the most common histologic type. Multiagent chemotherapy was mainstay of treatment. OS and EFS were 88.8% and 84.5%, respectively. OS in patients with or without bulky disease was 53.3% and 92.2%, respectively. Older age (≥10 years), presence of bulky disease, low hemoglobin (≤7.0 g/dl), and high leukocyte count (≥12000/mm3) at the time of diagnosis, and protocol used (cyclophosphamide, vincristine, procarbazine, and prednisone) were the risk factors for relapse. Conclusions: Our patient population had younger age, advanced disease, more B symptoms, and bulky disease. Still, we achieved good OS and EFS with chemotherapy-alone protocols. Patients with bulky disease had poor OS and EFS. If radiotherapy is included in the protocol for bulky disease, the survival rates can be improved further.http://www.ijmpo.org/article.asp?issn=0971-5851;year=2019;volume=40;issue=3;spage=341;epage=346;aulast=Guptachemotherapyhodgkin's diseaselymphadenopathylymphomasurvival
spellingShingle Vineeta Gupta
Tej Bali Singh
Sanjeev Kumar Gupta
Response and relapses in pediatric Hodgkin's Lymphoma treated with chemotherapy alone
Indian Journal of Medical and Paediatric Oncology
chemotherapy
hodgkin's disease
lymphadenopathy
lymphoma
survival
title Response and relapses in pediatric Hodgkin's Lymphoma treated with chemotherapy alone
title_full Response and relapses in pediatric Hodgkin's Lymphoma treated with chemotherapy alone
title_fullStr Response and relapses in pediatric Hodgkin's Lymphoma treated with chemotherapy alone
title_full_unstemmed Response and relapses in pediatric Hodgkin's Lymphoma treated with chemotherapy alone
title_short Response and relapses in pediatric Hodgkin's Lymphoma treated with chemotherapy alone
title_sort response and relapses in pediatric hodgkin s lymphoma treated with chemotherapy alone
topic chemotherapy
hodgkin's disease
lymphadenopathy
lymphoma
survival
url http://www.ijmpo.org/article.asp?issn=0971-5851;year=2019;volume=40;issue=3;spage=341;epage=346;aulast=Gupta
work_keys_str_mv AT vineetagupta responseandrelapsesinpediatrichodgkinslymphomatreatedwithchemotherapyalone
AT tejbalisingh responseandrelapsesinpediatrichodgkinslymphomatreatedwithchemotherapyalone
AT sanjeevkumargupta responseandrelapsesinpediatrichodgkinslymphomatreatedwithchemotherapyalone